Teledyne shares rise after first earnings report since Flir acquisition
Teledyne Technologies crushed analysts’ expectations July 28, delivering revenue in the second quarter of 2021 that doubled its total from the same quarter a year ago, thanks in large part to its acquisition of Flir systems, an Oregon based company with significant operations in Goleta. Teledyne, a Thousand Oaks-based industrial and scientific conglomerate, generated $1.12 Read More →
Read More →Amgen to buy biotech startup TeneoBio
Amgen announced July 27 that it plans to buy a privately held Bay Area biotech company called TeneoBio in an all-cash deal worth as much as $2.5 billion. The deal is expected to close in the second half of this year and calls for Amgen to pay $900 million up front for all outstanding shares Read More →
Read More →Takeda expansion is latest coup for Conejo Valley pharma industry
Takeda Pharmaceuticals, a Japanese company with major operations in the Conejo Valley, will expand its facility in Thousand Oaks, investing $126 million to build out the manufacturing operations to support new product lines. The Takeda team, alongside the mayor of Thousand Oaks, Claudia Bill-de la Peña, is scheduled to hold a groundbreaking ceremony for the Read More →
Read More →Teledyne secures Navy contract worth up to $39M
Thousand Oaks-based Teledyne Technologies announced July 19 that its subsidiary, Teledyne Brown Engineering, was awarded a U.S. Navy contract for underwater drones worth as much as $39.2 million. The contract has a maximum base value of $27.4 million over five years, with five one-year option periods and a maximum value of $39.2 million if all Read More →
Read More →
Amgen planning apartments on its land in Thousand Oaks
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Thousand Oaks biotech firm closes $140M funding round
Capsida Biotherapeutics, a biotechnology startup based in Thousand Oaks, announced April 29 that it is emerging from “stealth mode” with a $140 million funding round led by Westlake Village BioPartners and Versant Ventures. The Series A round includes $50 million from Westlake Village BioPartners, a venture capital firm in Thousand Oaks focused on biotech startups Read More →
Read More →Our View: Thousand Oaks takes smart route to growth
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
